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Abstract 
As part of its single technology appraisal (STA) process, the National Institute for Health and Care 
Excellence (NICE) invited the company that manufactures ponatinib (Inclusig®; Incyte Corporation) 
to submit evidence for the clinical and cost-effectiveness for previously treated chronic myeloid 
leukaemia (CML) and Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL). 
This paper focusses on the 3 phases of CML: chronic phase (CP), the accelerated phase (AP) and the 
blast crisis phase (BP). The School of Health and Related Research Technology Appraisal Group at 
the University of Sheffield were commissioned to act as the independent Evidence Review Group 
(ERG). 7KLV DUWLFOH SUHVHQWV WKH FULWLFDO UHYLHZ RI WKH FRPSDQ\¶V VXEPLVVLRQ E\ WKH (5* Dnd the 
outcome of the NICE guidance. 
 
Clinical evidence for ponatinib was derived from a Phase II, industry-sponsored, single-arm, open-
label, multicentre, non-comparative study. Despite the limited evidence and potential for biases, this 
study demonstrated that ponatinib was likely to be an effective treatment (in terms of major 
cytogenetic response [MCyR] and major haematologic response [MaHR]) with an acceptable safety 
profile for patients with CML. Given the absence of any head-to-head studies comparing ponatinib 
with other relevant comparators the company undertook a matching-adjusted indirect comparison 
(MAIC) of ponatinib with bosutinib. The approach was only used for patients with CP-CML because 
comprehensive data were not available for the AP- or BP-CML groups to allow the matching 
technique to be used. Despite the uncertainty about the MAIC approach, ponatinib was considered 
likely to offer advantages over bosutinib in the third line setting, particularly for complete cytogenetic 
response. 
 
The company developed two health economic models to assess the cost-effectiveness of ponatinib for 
the treatment of patients in CP-CML or in advanced CML (AP- or BP- CML, which were modelled 
separately). The company did not adequately explore the uncertainty in the survivor functions. As a 
result, the ERG believed the uncertainty in the decision problem was underestimated. Exploratory 
analyses undertaken by the ERG produced the following results for ponatinib.  In CP-CML, from 
£18,246 to £27,667 per quality-adjusted life year (QALY) gained compared with best supportive care 
(BSC), from £19,680 to £37,381 per QALY gained compared with bosutinib and from £18,279 per 
QALY gained to dominated compared with allogeneic stem cell transplant (allo-SCT). In AP-CML 
the cost per QALY gained for ponatinib ranged from £7,123 to £17,625 compared with BSC, and 
from dominating to £61,896 per QALY gained compared with allo-SCT. In BP-CML the cost-
effectiveness of ponatinib ranged from £5033 per QALY gained to dominated compared with allo-
SCT, although was likely to be at the more favourable end of this range, and dominant in all scenarios 
compared with BSC. The NICE appraisal committee concluded that ponatinib is a cost-effective use 
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of NHS resources in the considered population, subject to the company providing the agreed discount 
in the Patient Access Scheme. 
 
 
Key points for decision makers 
x There is uncertainty in the relative efficacy of ponatinib because of the main clinical evidence 
being derived from a non-comparative study.  
x The cost per quality-adjusted life year (QALY) gained values for ponatinib compared with 
bosutinib, allogeneic stem cell transplant and best supportive care were uncertain because of 
the uncertainty associated with extrapolated survivor functions. 
x The exploratory analyses performed by the Evidence Review Group provided ranges in which 
the cost per QALY gained were likely to fall for patients with Chronic Phase-, Accelerated 
Phase, and Blast Crisis Phase-chronic myeloid leukaemia. These ranges included values 
which fall both above and below the National Institute for Health and Care Excellence  
reported cost-effectiveness thresholds of typically between £20,000 and £30,000 per QALY 
gained. 
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1. Introduction 
The National Institute for Health and Care Excellence (NICE) is an independent organisation 
responsible for providing national guidance on promoting good health and preventing and treating ill 
health in priority areas with significant impact. Health technologies must be shown to be clinically 
effective and to represent a cost-effective use of National Health Service (NHS) resources in order for 
NICE to recommend their use within the NHS in England. The NICE Single Technology Appraisal 
(STA) process usually covers new health technologies within a single indication, soon after their UK 
market authorisation.[1]  Within the STA process, the company provides NICE with a written 
VXEPLVVLRQDORQJVLGHDPDWKHPDWLFDOPRGHOWKDWVXPPDULVHVWKHFRPSDQ\¶VHVWLPDWHVRIWKHFOLQLFDO
and cost-effectiveness of the technology. This submission is reviewed by an external organisation 
independent of NICE (the Evidence Review Group [ERG]), which consults with clinical specialists 
DQG SURGXFHV D UHSRUW $IWHU FRQVLGHUDWLRQ RI WKH FRPSDQ\¶V VXEPLVVLRQ WKH (5* UHSRUW DQG
testimony from experts and other stakeholders, the NICE Appraisal Committee (AC) formulates 
preliminary guidance, the Appraisal Consultation Document (ACD), which indicates the initial 
decision of the AC regarding the recommendation (or not) of the technology. Stakeholders are then 
invited to comment on the submitted evidence and the ACD, after which a further ACD may be 
produced or a Final Appraisal Determination (FAD) issued, which is open to appeal. An ACD is not 
produced when the technology is recommended within its full marketing authorisation; in this case, a 
FAD is produced directly. 
 
This paper presents a summary of the ERG report[2] for the STA of ponatinib for the treatment of 
chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukaemia (CML) in 
patients whose disease is resistant to dasatinib or nilotinib, who are intolerant to dasatinib or nilotinib 
and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the 
Threonine-315-Isoleucine (T315I) mutation. A summary of the subsequent development of the NICE 
guidance for the use of this technology in England is also provided. Full details of all relevant 
appraisal documents (including the appraisal scope, ERG report, company and consultee submissions, 
FAD and comments from consultees) can be found on the NICE website.[2]  
 
2. The Decision Problem 
CML is a rare type of cancer affecting the blood and is characterised by a proliferation of 
granulocytes in the bone marrow and blood.[3]  Approximately 95% of patients with CML have an 
acquired chromosomal abnormality (known as Philadelphia chromosome positive disease, Ph+) 
caused by reciprocal translocations between chromosomes 9 and 22.[4, 3]  CML occurs in all age 
groups, but is most common in older adults (median age at diagnosis in the UK is 59 years).[5]  CML 
is typically characterised as having three distinct phases: the initial indolent chronic phase (CP-CML) 
which lasts for several years, an intermediate accelerated phase (AP-CML) which lasts for less than 1 
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to 1.5 years, and an aggressive blast phase (BP-CML) that is usually fatal within 3 to 6 months.[6]  
The stage of the disease at diagnosis is an important prognostic factor and may predict the pattern of 
disease progression.[7]  In general, around 90% of CML cases are diagnosed during the chronic 
phase, with approximately 40% being asymptomatic and diagnosed as a result of a routine blood 
test.[3] From the chronic phase, patients with CML either go through the accelerated phase or move 
directly into blast crisis in which the disease transforms into a fatal acute leukaemia.[3] The phases 
are defined mainly by the percentage of blast cells in the blood and bone marrow.[8]  
 
2.1 Current Treatment 
The management of patients with CML is complex. Allogeneic stem cell transplant (allo-SCT) is the 
only potentially curative treatment for CML. However, it is associated with a substantial rate of 
morbidity and mortality and is therefore limited by patient suitability as well as the availability of 
suitable donors.[9] The use of oral tyrosine kinase inhibitors (TKIs) has become the mainstay of 
treatment in CML. Currently, five TKIs (imatinib,[10] dasatinib,[11] nilotinib,[12] bosutinib[13] and 
ponatinib)[14] have a European Union marketing authorisation for the treatment of CML.  
 
Guidance issued by NICE recommends imatinib (standard dose) or dasatinib and nilotinib (with a 
Patient Access Scheme [PAS]) as first-line treatment options for adults with Ph+ CP-CML.[15]  
Imatinib is also recommended as an option for the treatment of patients with Ph+ CML who initially 
present in the AP or BP, and for CML that presents in the CP and then progresses to the AP/BP, if 
imatinib has not been used previously (see TA70).[16]   It is noteworthy that the UK patent protection 
for imatinib was expected to expire during the STA and substantial cost reductions were expected 
with generic imatinib[17] which may lead to the potential for increased uptake. For second- and 
subsequent-line treatments, NICE recommends dasatinib and nilotinib (with a PAS) for patients with 
Ph+ CP-CML and AP-CML where treatment with imatinib is not tolerated or where there is 
resistance.[18] 
 
Furthermore, sequential use of second-generation TKIs such as dasatinib after nilotinib is common in 
UK clinical practice and is also recommended in European clinical practice guidelines.[9] However, 
there is a lack of clinical evidence to support the benefit of sequential use of second-generation TKIs 
in patients who are resistant/intolerant to prior therapy and sequential use is not an approved 
indication for these drugs.[11, 10] 
 
Bosutinib (with a PAS) was recently recommended by NICE as an option, within its conditional 
marketing authorisation, for Ph+ CP, AP- and BP-CML in adults when they have previously had one 
or more TKI; and imatinib, nilotinib and dasatinib are not appropriate.[19] The ERG notes that 
although bosutinib may be an option for some patients as a second-line treatment (if other second-
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generation TKI drugs are not suitable), bosutinib is likely to be predominantly used third-line or later 
in clinical practice.[20]  Other treatment options for patients with TKI resistant/intolerant CML 
include interferon alfa (in rare cases), best supportive/palliative care (including hydroxycarbamide), 
and allo-SCT. 
 
3. The Independent ERG Review 
In accordance with the process for STAs, the ERG and NICE had the opportunity to seek clarification 
RQVSHFLILFSRLQWVLQWKHFRPSDQ\¶VVXEPLVVLRQ&6[21]  in response to which the company provided 
additional information.[22] 7KH(5*DOVRPRGLILHGWKHFRPSDQ\¶VGHFLVLRQDQDO\WLFPRGHOWRSURGXFH
an ERG base case and to assess the impact of alternative parameter values and assumptions on the 
PRGHO UHVXOWV7KH HYLGHQFH SUHVHQWHG LQ WKH FRPSDQ\¶V VXEPLVVLRQ DQG WKH (5*¶V UHYLHZ RI WKDW
evidence is summarised here. 
 
3.1 Clinical Evidence Provided by the Company 
The CS[21] included a systematic review of the clinical effectiveness evidence of ponatinib for the 
treatment of CML. In the absence of randomised controlled trial evidence, the company identified two 
relevant single-arm, non-comparative studies (a Phase I dose finding study[23, 24] and a Phase II 
study).[25-27] However, the design and context of the Phase I study was not deemed entirely relevant 
to either the recommended dose or the licenced indication. As such, evidence from the Phase II PACE 
study formed the main pivotal evidence in the CS.[21] In reporting the data 95% confidence intervals 
(CI) are replicated where these were provided by the company. 
 
The PACE study was an industry-sponsored, single-arm, non-comparative, open-label, multicentre 
study (66 sites across 12 countries including five sites in the UK) designed to evaluate the efficacy 
and safety of ponatinib (administered orally at a starting dose of 45mg once daily), in 449 patients 
(53% male; 78% Caucasian) with CP-CML (n=270), AP-CML (n=85), BP-CML (n=62) or Ph+ acute 
lymphoblastic leukaemia (n=32) who were resistant or intolerant to either dasatinib or nilotinib, or 
who had the T315I mutation after any TKI therapy (as confirmed by direct sequencing).[26, 28, 29]  
 
Study participants in the PACE study were heavily pre-treated with prior TKIs and conventional 
therapy: 37% (167/449) had received two TKIs (imatinib, dasatinib, nilotinib or bosutinib). This 
SRSXODWLRQ FRPSULVHG WKH WDUJHW SRSXODWLRQ LQ WKH FRPSDQ\¶V GHFLVLRQ SUREOHP IRU &3-CML, AP-
CML and BP-CML i.e. in the third-line treatment setting, reflecting the anticipated place in therapy of 
ponatinib, after treatment failure with imatinib and either nilotinib or dasatinib.  
 
For CP-CML patients, the primary outcome measure was the proportion of patients achieving major 
cytogenetic response (MCyR, defined as complete cytogenetic response or partial cytogenetic 
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response) within 12 months of starting treatment. For patients with AP-CML and BP-CML, the 
primary outcome measure was the proportion of patients achieving a major haematologic response 
(MaHR, defined as complete haematologic response or no evidence of leukaemia, confirmed by blood 
analyses) within 6 months of starting treatment.  
 
Among the subgroup of CP-CML patients who received third-line ponatinib (i.e. the main target 
population in the CS), 67% (95% CI: 57%, 76%) achieved MCyR by 12 months (primary endpoint). 
In an updated analysis (at a median follow up of 48.2 months),[27] 71% of CP-CML patients (n=97) 
achieved MCyR and an estimated 88% of responding patients maintained this response for at least 3 
years. At 4 years, progression-free survival (defined as death, development of AP or BP, loss of 
complete haematologic response in absence of cytogenetic response, loss of MCyR, or increasing 
white blood cell count without complete haematologic response) and overall survival rates in CP-
CML patients who received ponatinib third-line were 68% and 79%, respectively (median not reached 
for either outcome).  Ponatinib is the only TKI with activity against the T315I mutation.  Among the 
subgroup of CP-CML patients who had the T315I mutation (n=64, all lines [data were not reported 
separately by line of therapy])[26] 70% achieved an MCyR by 12 months. In an updated analysis at 4 
years,[30] 72% of CP-CML patients achieved a MCyR, progression-free survival was 56% and 
overall survival was 72%. 
 
In the subgroup of AP-CML patients (n=33) who received ponatinib third-line, 61% had an MaHR 
within the first 6 months (primary endpoint). Among those who had the T315I mutation (n=18, all 
lines), 50% achieved an MaHR by 6 months.  Overall and progression-free survival was not reported.  
Among patients with BP-CML (all lines, n=62 [data not reported separately by line of therapy]), 31% 
(95% CI: 20%, 44%) achieved an MaHR within the first 6 months (primary endpoint). The rates of 
progression-free survival and overall survival at 12 months were estimated to be 19% (median 4 
months) and 29% (median 7 months), respectively. Among the BP-CML patients who had the T315I 
mutation (n=24, all lines), 29% had an MaHR within the first 6 months.[26] Overall and progression-
free survival was not reported. The ERG believes that caution should be used in the interpretation of 
the data because of the small population size and study design limitations. 
 
At the latest data cut for treatment discontinuation among CML patients who received at least one 
dose of the study drug (all lines), 18.5% of CP-CML patients (n=270), 11.8% of AP-CML patients 
(n=85), and 14.5% of BP-CML patients (n=62) withdrew from treatment because of adverse 
events.[26]  
In terms of safety, at the last data-cut where data can be presented the following severe, or life-
threatening treatment-related adverse events were observed: thrombocytopenia (CP-CML 32%, AP-
CML 33%, BP-CML 26%), neutropenia (CP-CML 14%, AP-CML 26%, BP-CML 18%); increased 
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lipase (CP-CML 10%, AP-CML 13%, BP-CML 11%) and anaemia (CP-CML 6%, AP-CML 9%, BP-
CML 21%). All other serious or life-threatening treatment-related adverse events occurred in less than 
10% of patients. [26] 
 
Given the absence of any head-to-head studies comparing ponatinib with other relevant comparators 
for the treatment of CP-CML, the company undertook a matching-adjusted indirect comparison 
(MAIC) to facilitate an indirect comparison between treatments and to inform the economic model. 
The objective of the MAIC was to adjust outcomes to account for imbalances between treatments in 
(observed) prognostic factors in different studies; prognostic factors were T315I mutation status, sex, 
median age, race, duration of CML, and Eastern Cooperative Oncology Group (ECOG) performance 
status. The main effectiveness outcome measures for the MAIC were cytogenetic best response rates, 
haematologic best response rates and duration of response. The MAIC adjusted responses to ponatinib 
in the PACE study (Phase II) as if ponatinib had been included in the Phase I/II study[31] that 
evaluated bosutinib rather than adjusting responses to bosutinib as if it had been included in the PACE 
study. From the MAIC, the company estimated that ponatinib provided considerably higher complete 
cytogenetic response rates than bosutinib in the third-line (61% versus 24%) 7KH (5*¶V PDLQ
critique of the MAIC was that indirect estimates of treatment effect may be biased as a consequence 
of unmeasured confounders, although clinical input to the ERG did not highlight any important 
omissions. In addition, no adjustment was made to other outcomes, including overall survival and 
adverse events, or for any AP-CML, and BP-CML outcomes. 
 
3.1.1 Critique of the Clinical Evidence and Interpretation 
The systematic review process followed by the company was reasonably comprehensive. Despite 
PLQRU OLPLWDWLRQV LQ WKH FRPSDQ\¶V VHDUFK VWUDWHJ\ WKH (5* ZDV UHDVRQDEO\ FRQILGHQW WKDW DOO
relevant published studies (randomised controlled and non-randomised/non-controlled evidence) of 
ponatinib were included in the CS, including data from ongoing studies. Based on the quality 
assessment tool for non-randomised studies,[32] the ERG considered the PACE study to be a well-
reported and conducted single-arm study. However, single-arm studies are associated with an array of 
potential biases[33] including a high risk of selection bias (because of the absence of randomisation), 
and performance and detection bias (because of the absence of blinding).[34, 35] In addition, because 
of the absence of a comparator group in the PACE study, inferences about treatment effects were 
made indirectly to a Phase I/II study of bosutinib using MAIC as if ponatinib has been included in that 
study.  A further limitation to the robustness of the efficacy and safety data relate to the small 
subgroups that comprise the target population in the CS.  
 
The key uncertainties in the clinical evidence relate to optimal dosing, duration of treatment and the 
unbiased estimate of treatment effect. In the PACE study,[26] patients received an initial dose of 
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45mg of ponatinib orally once daily; however, dose adjustments (e.g. lowering of the dose to 30mg or 
15mg once daily and frequency of treatment) were allowed for the management of treatment toxicity.  
As such, it remains unclear if the adjusted lower dosing regimens would have been clinically effective 
over the entire PACE study period. In addition, no data were available on the alternative treatments 
given to patients who stopped study treatment in the PACE study. Clinical advisors to the ERG 
commented that in UK practice, stopping treatment is dependent on patient choice, but clinicians 
would discourage patients from doing so if they were not in complete remission. The summary of 
product characteristics posology recommends considering discontinuing ponatinib if a complete 
haematologic response has not occurred by 3 months (90 days).[14] The PACE study reported 
outcomes over a median follow-up of 48.2 months (4 years).[27] As a result, the longer term safety 
and efficacy of ponatinib is currently unknown.  
 
3.2 Cost-Effectiveness Evidence Provided by the Company  
The company developed two health economic models to assess the cost-effectiveness of ponatinib for 
the treatment of patients in CP-CML or in advanced CML (AP- or BP-, which were modelled 
separately). Both models adopted the perspective of the NHS and Personal Social Services over a 
lifetime horizon and discounted both quality-adjusted life-years (QALYs) and costs at a rate of 3.5% 
per annum. The model employed a state transition approach, with three-monthly time cycles and 
included a half-cycle correction. The models that were originally submitted were amended by the 
company following the clarification process: only the revised models are detailed here. The company 
initially provided a simple discount to the price of ponatinib via a PAS, the value of which is 
commercial in confidence. During the consultation process, the company submitted a revised PAS, 
with a larger discount. Only results incorporating the revised PAS are presented within this report. 
 
3.2.1 Model structures presented by the company 
3.2.1.1 CP-CML model 
Within the CP-CML model, a hypothetical patient could receive one of five interventions: (i) 
ponatinib; (ii) bosutinib; (iii) hydroxyurea, representing best supportive care (BSC); (iv) interferon 
alfa or (v) allogeneic stem cell transplant (allo-SCT).  
 
The simulated patients receiving non-allo-SCT treatments were distributed amongst four response 
states (i) complete cytogenic response (CCyR); (ii) partial cytogenic response (PCyR); (iii) complete 
haematologic response (CHR) or (iv) no response (NR). In subsequent cycles, patients receiving 
pharmacological treatments could continue in their current response state, experience disease 
progression to AP-CML, lose response within the CCyR and PCyR states, or die. Patients receiving 
an allo-SCT could continue in a post allo-SCT state, experience remission or die. Patients were at risk 
of all-cause mortality and CML associated mortality. However, CML associated mortality applied 
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only to patients who had progressed to AP-CML. All-cause mortality was based on mortality 
functions for the general population.[36] Patients receiving allo-SCT in the CP-CML state were 
assumed to enter a relapse-free state, from which they could die or relapse: within the relapse state 
only death could occur. Following allo-SCT the model assumed the same life expectancy for those 
who relapsed and for those who did not; although a utility difference was assumed. 
  
$ NH\ GULYHU RI SDWLHQWV¶ ORQJ-term prognoses, both in terms of life expectancy and utility, is the 
assumed response rates for non-allo-SCT treatments. As previously stated, these were divided into 
CCyR; PCyR; CHR; and NR for those in CP-CML, whereas for those in in AP-CML and BP-CML 
there were only two health states, MaHR or NR.  
 
In patients with CP-CML, response probabilities for ponatinib were taken from the PACE study,[26] 
whilst probabilities for bosutinib were taken from Khoury et al.[31] The company assumed that 
patients receiving BSC or interferon alfa would not achieve either CCyR or PCyR but could achieve 
CHR with a probability taken from Dalziel et al.[37] The response probabilities assumed by the 
company for each treatment are presented in Table 1. The summary of product characteristics[38] 
suggest stopping ponatinib if there had not been at least a CHR in the initial three months and 
reducing the dose to 15mg if there has been a MaHR. The model assumed that ponatinib treatment 
was discontinued if the patient experienced NR. 
 
Table 1: Response probabilities assumed by the company  
Treatment 
 
Response level Source 
 CCyR PCyR CHR NR 
Ponatinib 61.34% 8.46% 18.19% 21.01% Matched Adjusted 
Indirect Comparison 
Bosutinib 24.07% 8.33% 37.93% 29.66% Khoury et al.[31] 
Hydroxyurea* - - 41% 59% Dalziel et al.[37] 
Interferon alfa - - 47% 53% Dalziel et al.[37] 
      
CCyR, complete cytogenetic response; PCyR,partial cytogenetic response; CHR, complete haematologic response; NR, no response 
* Assumed to represent best supportive care 
 
The duration of response in CP-CML before progression to AP-CML was taken from the BMS-043 
study reported by Loveman et al.[39] and reproduced in Table 2. These data were extrapolated using 
survival functions which were chosen by the company based on the observed fit, using the Akaike 
information criterion (AIC) and Bayesian information criterion (BIC) and clinical plausibility. 
Gompertz distributions were chosen for CCyR and PCyR, a Weibull distribution was used for CHR, 
and an exponential distribution for NR.  
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Table 2: Duration of response in CP-CML before progression to AP-CML[39]   
Month Best response level 
CCyR PCyR CHR NR 
0 100.0% 100.0% 100.0% 100.0% 
6 100.0% 100.0% 94.9% 30.0% 
12 98.2% 94.4% 84.1% 30.0% 
18 98.2% 83.3% 77.7% 30.0% 
24 94.2% 83.3% 63.6% 30.0% 
30 94.2% 83.3% 55.9% 30.0% 
36 94.2% 77.8% 38.7% 30.0% 
42 94.2% 71.3% 25.8% 25.8% 
48 94.2% 59.4% 25.8% 24.1% 
CCyR, complete cytogenetic response; PCyR,partial cytogenetic response; CHR, complete haematologic response; NR, no response 
 
Loss of CCyR and PCyR responses were assumed to differ between bosutinib and ponatinib. For 
ponatinib, the company fitted standard parametric models to data from the PACE study[26] for 
patients with CCyR and PCyR using response level as a covariate. The Gompertz distribution was 
selected by the company as most appropriate for loss of response. For bosutinib, data from 
Gambacorti-Passerini et al.[40], which combined patients with PCyR and CCyR, were digitised by 
the company parameters estimated using the Solver function in Microsoft Excel® by minimising the 
sum of squared errors (SSE) for different survivor functions. Although this method provides estimates 
of the parameters for each survivor function, it provides no meaningful estimates of the variances (and 
covariances) associated with the parameters. The Gompertz distribution was selected by the company 
as most appropriate for loss of response and used for patients with either a CCyR or a PCyR.  
 
Time until treatment discontinuation was assumed to differ between ponatinib and bosutinib. For 
bosutinib the company used data from Khoury et al.[31]  to fit an exponential distribution, which was 
assumed applicable for CCyR, PCyR and CHR. For ponatinib, the company fitted standard parametric 
models separately to CCyR PCyR and CHR using data from the PACE study[26] and selected the 
exponential distribution LQ DOO FDVHV µfor consistency with the function used for bosutinib¶ 3DWLHQWV
discontinuing treatment in CCyR were assumed to remain in that state. Patients discontinuing in the 
PCyR and CHR states were allocated to either the CHR state (41%) or the NR state (59%) based on 
the reported efficacy of hydroxurea[37] which was assumed generalisable to BSC. Patients receiving 
interferon-alfa or BSC would not have their treatment discontinued. 
 
The pathway for patients who progressed to AP-CML from CP-CML was dependent on whether the 
patient was suitable for allo-SCT, the proportion of which was assumed to be 27.3% based on a UK 
survey conducted by the company. Following progression from the CP-CML health state, the model 
estimated the costs incurred and QALYs accrued in the AP-CML and the BP-CML phases and added 
these to the values accrued in the CP-CML stage.  
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For those patients in AP-CML not suitable for allo-SCT, possible transitions were to BP-CML or 
death. The company assumed that whilst in AP-CML patients would be treated with one of the 
following: dasatinib, nilotinib, bosutinb, imatinib and BSC, with each having a 20% proportion of 
market share. The probability of death in AP-CML was estimated by the company using data from 
Kantarjian et al.[41] The data were digitised and parametric distributions were fitted to the data in 
Microsoft Excel. The company selected the log-normal distribution as the most appropriate 
distribution. The risk of progression from AP-CML to BP-CML was estimated by the company using 
data in Kantarjian et al.[41] which reported that the mean progression-free survival in AP-CML was 
9.16 months: this value was used to derive an exponential function. For patients who progressed to 
BP-CML the probability of death was estimated using data from Kantarjian et al.[41] and the method 
used in AP-CML. The company selected the log-logistic distribution as the most appropriate 
distribution. The duration in AP-CML before progressing to BP-CML was considered independent of 
prior treatment in CP-CML. Overall survival was extrapolated with the company selecting the log-
normal distribution for overall survival in AP-CML and the log-logistic distribution in BP-CML. 
 
For patients suitable for allo-SCT the durations of overall survival were extrapolated by fitting 
parametric survival models to data extracted from an observational study conducted by Jabbour et 
al.[42] The company selected the exponential distribution for both CP-CML and AP-CML: patients in 
the CP-CML model were assumed ineligible to receive an allo-SCT if they had progressed to BP-
CML. The company assumed that relapse free survival following allo-SCT was the same regardless of 
whether the patient was in CP-CML or AP-CML. The duration of relapse free survival data were 
extrapolated by fitting parametric survival models to data reported in Craddock et al.[43] 
 
The model included the following ponatinib-related serious adverse events: arterial occlusive events 
(cardiovascular, cerebrovascular, peripheral vascular events) and venous thromboembolism events, 
which were assumed to have a risk of recurrence. Other serious adverse events (grade 3 or 4) were 
included if at least 5% of the PACE study population experienced the event, but these were only 
assumed to occur in the first cycle (3 months). Patients treated with bosutinib were assumed to have 
no serious adverse events as reported in Kantarjian et al.[44] BSC; interferon alfa, and allo-SCT were 
not assumed to have adverse events, although the mortality rates post allo-SCT were assumed to be 
significantly higher than in the general population with CP-CML. The same adverse events were 
included in the AP- and BP-CML models, although the incidence differed by stage of CML. 
 
Health-related quality of life used in the model were based on those reported by Kind et al.[45] The 
model used utility decrements for the various disease states based on data reported by Szabo et al.[46] 
The disutility associated with CP-CML, AP-CML and BP-CML were 0.116, 0.316 and 0.556, 
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respectively. CP-CML patients who have CCyR were assumed to experience no disease related 
disutility. The disutility associated with adverse events serious enough to require treatment 
discontinuation (0.326) was taken from Szabo et al.[46] Disutility following allo-SCT was assumed to 
decrease over time. Disutility in the first three months was 0.296 based on data reported by Van 
Agthoven et al.[47] Disutility six months after allo-SCT was 0.136 based on data in Loveman et 
al.,[39] with the average of these two values used for the three to six month period after allo-SCT. 
Following relapse after an allo-SCT a disutility of 0.260 was used based on data reported by 
Kantarjian et al.[48] and Olavarria et al.[49] These utility data were also used in the AP- and BP-
CML models. 
 
The cost of three months of treatment with bosutinib, interferon alfa and hydroxyurea were assumed 
to be £10,714, £6,833 and £38 respectively. The cost associated with an allo-SCT was £60,092 with 
follow up costs of £12,215, £3,518 and £420 in years 1, 2 and 3 and subsequent respectively based on 
data from the UK stem cell oversight committee[50] and the HTA report published for bosutinib.[20] 
The cost of ponatinib was commercial-in-confidence because of both the PAS and the relative dose 
intensity observed in the PACE study.[26] These cost data were also used in the AP- and BP-CML 
models. The components of each cost estimate were valued at 2014/15 prices unless a more recent 
value was available. 
 
For non-allo-SCT patients, based on a survey undertaken by the company the number of days in 
hospital per cycle was assumed to be zero for those with CP-CML, 2.13 days for patients with AP-
CML and 26.64 for patients with BP-CML. Monitoring costs were assumed to be independent of 
treatment. The per cycle hospitalisation and monitoring costs for CP-CML (responding), CP-CML 
(non-responding), AP-CML and BP-CML were £208, £495, £2,648 and £20,319 respectively. End-of-
life care was assumed to cost £5,766 based on resource use estimated in a UK clinical expert survey 
conducted by the company. These cost data were also used in the AP- and BP-CML models. The 
components of each cost estimate were valued at 2014/15 prices unless a more recent value was 
available. 
 
3.2.1.2 AP- and BP- CML models 
The CP-CML model structure described earlier was used to evaluate the cost-effectiveness of 
ponatinib for both patients with AP-CML and for patients with BP-CML. Having entered the model, a 
hypothetical patient could receive one of four treatments (i) ponatinib; (ii) bosutinib; (iii) BSC or (iv) 
immediate allo-SCT, if the patients were eligible. Ponatinib and bosutinib were used as a bridge to 
allo-SCT, with patients experiencing an MaHR progressing to allo-SCT. 
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Simulated patients who entered the model after receiving ponatinib or bosutinib had one of two 
responses: MaHR or NR. MaHR could only occur in the first cycle (3 months), with patients 
achieving MaHR receiving an allo-SCT. Patients who entered the AP-CML model and had NR were 
assumed to discontinue ponatinib treatment but not bosutinib. These patients could remain in NR, 
progress to BP-CML where BSC is provided, or die. Patients who received an allo-SCT entered a post 
allo-SCT health state and in subsequent cycles either remained in that state or died. The prognoses for 
patients who received an allo-SCT after achieving an MaHR were assumed better than for patients 
who had allo-SCT immediately. 
 
Patients who entered the model with BP-CML could receive ponatinib, bosutinib or BSC. Patients 
experiencing an MaHR will receive an allo-SCT, the remainder discontinue ponatinib treatment, but 
not bosutinib treatment and each cycle remain in NR or die. MaHR response data for each treatment 
are presented in Table 3 and represent a naïve indirect comparison. 
 
Table 3: MaHR responses assumed by the company  
Treatment Patients achieving a major haematologic 
response 
Source  
AP-CML BP-CML 
Ponatinib 55.70% 31.70% PACE trial[26] 
Bosutinib 29.20% 4.30% Gambacorti-Passerini et al.[40] 
BSC 0% 0% Company assumption 
AP-CML, accelerated phase chronic myeloid leukaemia; BP-CML, blast phase chronic myeloid leukaemia; BSC, best supportive care 
 
Patients in AP-CML who had allo-SCT after an MaHR were assumed to remain in this state until 
death. The assumed probability of death was estimated from data in Radich,[51] which provided data 
on the following three groups of patients: (i) those with AP-CML; (ii) those with BP-CML in 
remission; and (iii) those with BP-CML without remission. Patients with MaHR in AP-CML were 
assumed to be equivalent to those reported as in AP-CML by Radich[51] Parametric functions were 
fitted to the data by minimising the SSE, as previously described. The company did not select the 
distribution that fitted best according to AIC and BIC (the Gompertz distribution) but instead selected 
the exponential distribution as this was believed by the company to be more clinically plausible i.e. 
constant hazards. 
 
For patients with AP-CML who had NR, the time to progression to BP-CML was estimated by fitting 
parametric survival distributions to the data from the PACE study.[26] These data were marked as 
academic-in-confidence by the company. The survivor function used by the company relating to death 
for patients with AP-CML whilst in NR was also marked as academic-in-confidence. 
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Patients in AP-CML who had allo-SCT on entering the model were assumed to remain in this state 
until death. The probability of death was derived from Radich[51] assuming that the ratio between the 
two functions relating to BP-CML (remission and non-remission) would be applicable in AP-CML 
and that patients who had allo-SCT directly on entering the model were equivalent to AP-CML 
without remission, whereas those who had allo-SCT after MaHR were equivalent to allo-SCT with 
remission. 
 
For patients with BP-CML who had NR, the time to death was estimated by fitting parametric 
distributions to data from the PACE study.[26] These data were marked as academic-in-confidence by 
the company. The time to death for those who experienced NR whilst on bosutinib treatment was 
assumed to be equal to those who had received ponatinib treatment. For patients receiving BSC the 
probability of death was estimated using data from Kantarjian et al.[41] 
 
3.2.2. Results presented by the company 
As advised by NICE, all results presented by the company used the discounted price for ponatinib but 
the list price for comparators. 
 
3.2.2.1 CP-CML model 
Following the clarification process the base case incremental cost-effectiveness ratios (ICERs) 
estimated by the company for ponatinib versus bosutinib, BSC, interferon alfa and allo-SCT were 
£18,213; £15,200; £4042 and £6395 per QALY gained respectively. The probabilistic analysis of 
ponatinib versus bosutinib produced an ICER of £20,657 per QALY gained. The company conducted 
a number of sensitivity analyses, which showed that the results were sensitive to the costs associated 
with hospital admission in BP-CML. 
 
3.2.2.2 AP-CML model 
Following the clarification process the base case ICER estimated by the company for ponatinib versus 
bosutinib, BSC and immediate allo-SCT were dominant, £14,750 and £13,279 per QALY gained 
respectively. The probabilistic analysis of ponatinib versus BSC produced an ICER of £13,481 per 
QALY gained. The company conducted a number of sensitivity analyses which showed that the 
results were relatively robust to the changes explored. 
 
3.2.2.3 BP-CML model 
Following the clarification process the base case ICER estimated by the company for ponatinib versus 
BSC, immediate allo-SCT and bosutinib were dominant, dominant and £17,601 per QALY gained 
respectively. The probabilistic analysis of ponatinib versus bosutinib produced an ICER of £16,229 
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per QALY gained. The company conducted a number of sensitivity analyses which showed that the 
results were sensitive to the costs of hospitalisation in the BP-CML phase. 
 
3.3 Critique of the cost-effectiveness evidence and additional work undertaken by the ERG  
The ERG undertook a number of exploratory deterministic sensitivity analyses. Analyses that 
noticeably changed the ICER are detailed below. 
 
)LUVW WKH (5* EHOLHYHG WKDW WKH FRPSDQ\¶V VHOHFWLRQ RI GLVWULEXWLRQV XVHG for progression-free 
survival and overall survival functions was questionable. The ERG undertook further analyses to 
provide a range of plausible ICERs. The ERG generated parametric survival functions, where 
possible, using the method proposed by Guyot et al.[52] to reconstruct patient-level data and then 
using maximum likelihood estimation to fit the parametric distributions. Analyses were conducted in 
R using flexsurvreg. Second, clinical advice to the ERG suggested that the assumption made by the 
company that any missed doses will be saved by patients for later use (resulting in fewer packs of 
ponatinib and bosutinib being issued) was potentially plausible for patients in CP-CML but unlikely 
in AP- and BP-CML. The ERG conducted an analysis assuming full wastage of missed doses. Third, 
WKH FRPSDQ\¶V PRGHO DVVXPHV WKDW WUHDWPHQW ZLWK ERVXWLQLE XQOLNH SRQDWLQLE ZRXOG FRQWLQXH IRU
patients with NR in CP-CML, and for patients without MaHR in AP-CML and BP-CML. Based on 
clinical advice the ERG adapted the model so that the same stopping rules applied to both ponatinib 
and bosutinib. Fourth, the company applied a half cycle correction to the costs of pharmacological 
treatments. However, the ERG believes that once pharmacological treatments are issued to a patient 
any unused drugs would be disposed of and thus the half cycle correction was incorrect. The ERG 
acknowledges that this assumption will mean that costs are overestimated in this scenario as it 
unlikely that patients will be issued with three PRQWKV¶ treatment at once. Fifth, the survival estimated 
for these patients are not aligned with cost estimates. The ERG explored the impact of setting the 
costs of treatment post CP-CML progression and allo-SCT relapse equal to that of either BSC and the 
estimated costs of generic imatinib. Finally, the ERG explored the use of alternative survivor 
functions to those chosen by the company.  
 
$VXPPDU\RIWKHUHVXOWVRIWKH(5*¶VH[SORratory analyses are provided. The ERG did not believe 
that interferon-alfa would be on the efficiency frontier and so did not perform exploratory analyses 
versus this treatment. The ERG did not conduct further analyses comparing ponatinib with bosutinib 
in the AP- or BP-CML states as ponatinib was typically dominant. As instructed by NICE the results 
presented by the ERG contain the PAS for ponatinib but not for comparator treatments. 
 
3.3.1 CP-CML model 
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The combination of recalculating the survivor functions, incorporating a three month stopping rule for 
bosutinib, removing half cycle correction of interventions, reducing the costs associated with 
progressing beyond CP-CML, along with minor corrections produced the following range of ICERs 
for ponatinib: £18,246 to £27,667 per QALY gained compared with BSC; £19,680 to £37,381 per 
QALY gained compared with bosutinib; and £18,279 per QALY gained to dominated compared with 
allo-SCT. 
 
3.3.2 AP-CML model 
The combination of recalculating the survivor functions, adding in drug wastage, incorporating a three 
month stopping rule for bosutinib, removing half cycle correction of interventions, along with minor 
corrections produced the following range of ICERs for ponatinib: £7,123 to £17,625 per QALY 
gained compared with BSC; and from dominating to £61,896 per QALY gained compared with allo-
SCT.  
 
3.3.3 BP-CML model 
The combination of recalculating the survivor functions, adding in drug wastage, incorporating a three 
month stopping rule for bosutinib, removing half cycle correction of interventions, along with minor 
corrections produced the following range of ICERs for ponatinib: £5033 per QALY gained to 
dominated compared with allo-SCT, although likely to be at the more favourable end of this range; 
and dominant in all scenarios compared with BSC. The ERG did not conduct further analyses 
comparing ponatinib with bosutinib as ponatinib was typically dominant. 
 
3.4 Conclusions of the ERG Report  
The key clinical effectiveness evidence for ponatinib was derived from a single arm study of patients 
with CML (CP, AP or BP). As such, a MAIC was conducted to compare the response rates for 
ponatinib with bosutinib only in CP-CML patients (comprehensive data were not available for the AP 
or BP-CML group to allow the matching technique to be used). However, MAIC are biased because 
of unmeasured confounders. For AP- and BP-CML naïve indirect comparisons (which were 
considered biased) were necessary to compare ponatinib against bosutinib (excluding CP-CML), allo-
SCT and BSC. Naïve indirect comparison methods are considered to be equivalent to observational 
data and subject to similar biases.[53, 54] The exploratory analyses performed by the ERG provided 
the AC with ranges in which the ICERs were likely to lie for patients with CP-, AP-, and BP-CML . 
These ranges included values which fell both below and above 1,&(¶V UHSRUWHG FRVW-effectiveness 
thresholds, typically between £20,000 and £30,000 per QALY gained. 
 
4. Key Methodological Issues  
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Naïve indirect comparison methods are considered to be equivalent to observational data and subject 
to similar biases. Furthermore, analyses based on the MAIC approach are subject to potential biases 
because of unobserved confounders. As a result, the face validity of each naïve adjusted indirect 
comparison and MAIC should be carefully assessed. 
 
The exploration of the impact of using alternative, plausible survival functions on the ICER was not 
undertaken by the company. The analyses undertaken by the ERG indicates that the range of the ICER 
was large and that a decision based on an ICER from a single survival function could be misleading. 
 
5. National Institute for Health and Care Excellence Guidance  
In June 2017, on the basis of the evidence available (including verbal testimony of invited clinical 
experts and patient representatives), the NICE Appraisal Committee (AC) produced guidance that 
ponatinib was recommended as an option for treating adults with CP-, AP- or BP-CML  when the 
disease is resistant to dasatinib /nilotinib, or when the patient cannot tolerate dasatinib /nilotinib and 
for whom subsequent treatment with imatinib is not clinically appropriate, or the T315I gene is 
present and when the company provides the drug with the agreed PAS.[55] 
 
5.1 Consideration of Clinical and Cost-Effectiveness Issues Included in the Final Appraisal 
Determination (FAD) 
This section summarises the key issues considered by the AC. The full list of the issues considered by 
the AC can be found in the FAD.[55] 
 
5.1.1 Uncertainties in the Clinical evidence  
The AC noted the lack of a comparator in the PACE study,[26] ³but was aware of the ethical 
considerations (offering placebo to patients who have not responded to previous treatment) which 
prevented a randomised control trial design´. The AC was aware that for some patients in the study, 
the dosage was changed or treatment was stopped which led to uncertainties about the best dosing 
level, the duration of treatment, and the generalisability of the reported outcomes. The committee 
concluded that despite these uncertainties the evidence presented was sufficient for decision making. 
 
To allow for a comparison with bosutinib, the company presented an MAIC. The approach was only 
used for patients with CP-CML because comprehensive data were not available for the AP- or BP-
CML groups to allow the matching technique to be used. The AC noted the limitations of the 
company's MAIC but accepted that it could be used for decision-making. However, the AC concluded 
that the company had neither properly explored the effect of alternative parametric distributions nor 
justified its chosen distribution, but concluded that the alternative fitting undertaken by the ERG was 
appropriate. 
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5.1.2 Uncertainties in the Economic Modelling 
The AC noted that whilst the ERG stated that the probabilistic sensitivity analyses done by the 
company were not robust because of the inappropriate characterisation of uncertainty, including 
correlation, in survivor functions, and arbitrary choices of standard error to represent uncertainty, the 
model structure was appropriate for decision making. 
 
Following testimony from clinical experts which stated that clinicians would stop treatment with 
bosutinib or ponatinib as soon as possible if the disease were no longer responding to treatment, the 
AC concluded that a three-month stopping rule for bosutinib should be applied. 
 
The AC concluded that drug wastage should be assumed in AP- and BP-CML, and that zero wastage 
was unlikely to occur in CP-CML, and that some allowance should have been made for this, although 
it noted that this had only a small effect on the ICER.  
 
5.1.3 End-of-Life Criteria 
The AC concluded that the end-of-life criteria (a survival of less than 2 years and an extension of life 
of more than 3 months) had been met for the following groups only: for patients with AP-CML for 
whom allo-SCT or bosutinib were not appropriate and for patients with BP- CML. 
 
6. Conclusions 
The AC recognised that there was considerable uncertainty in the value of the ICERs, and therefore 
their most likely value fell within a range. The AC concluded that in all instances this range, when 
including PAS of other interventions used in the treatment of CML, included cost-effective values, 
and therefore ponatinib was a cost-effective use of NHS resources.  
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